Navigation Links
EMKinetics Announces Start of Pivotal Trial for the TranStim™ Transdermal Neuromodulation System
Date:10/14/2011

CAMPBELL, Calif., Oct. 14, 2011 /PRNewswire/ -- EMKinetics, Inc. announced today initiation of the TranStim™ Transdermal Neuromodulation System pivotal trial for patients suffering from urge incontinence and overactive bladder.  The 120-person trial will be conducted at 10-15 US centers.  Submission for CE mark and 510(k) clearance will follow the completion of the study.   EMKinetics' TranStim therapy builds on the body of evidence that posterior tibial nerve stimulation (PTNS) can generate a clinically significant improvement in patients suffering from urge incontinence and overactive bladder.  

"This appears to be the next evolutionary step for PTNS technology," said Marshall Stoller, MD, EMKinetics co-founder and professor and vice chair in the Department of Urology at the University of California, San Francisco. "We are confident that the TranStim System has the potential to safely and consistently provide transdermal PTNS therapy.  We believe this advancement will be well received by this desperate patient population and the physicians caring for them."  

The initiation of the pivotal trial follows the closing of EMKinetics' Series C financing of $8.0 million, led by a strategic investment from Allergan, Inc., a global multi-specialty healthcare company with a strong and growing urology portfolio.  Series B investor, Scientific Health Development, and four new institutional investors, Easton Capital, Oakwood Medical Investors, Legacy Life Sciences and Millennium Life Sciences Fund, filled out the round.

"Allergan, which is widely known for its specialty pharmaceuticals, has also become a significant participant in medical devices and is emerging as a leader in urologic therapies", said Daniel Burnett, MD, co-founder and director of EMKinetics. "Their financial support in an area they know so well is both gratifying and important to our company."

About EMKinetics, Inc.

The fourth venture-backed spin-out from incubator TheraNova, LLC, EMKinetics, Inc. is a clinical-stage medical technology company developing neuromodulation therapies based on its Transdermal Stimulation (TranStim™) technology. The EMKinetics technology focuses on neuromodulation for the treatment of overactive bladder and other maladies.  EMKinetics is headquartered in Campbell, CA.

EMKinetics, Inc. contact:
Hugh Sharkey, CEO
(650) 384-0008
www.EMKinetics.com


'/>"/>
SOURCE EMKinetics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... 2, 2017  Eli Lilly and Company (NYSE: ... the third quarter of 2017 on Tuesday, October 24, ... that day with the investment community and media to ... conference call will begin at 9 a.m. Eastern time. ... live webcast of the conference call through a link ...
(Date:9/28/2017)... Cohen Veterans Bioscience and Early Signal Foundation ... and home sensors for real-time monitoring of patients with ... nonprofit organization focused on disruptive health solutions for rare ... system to record and integrate behavioral, cognitive, physiological and ... ...
(Date:9/23/2017)... Janssen Biotech, Inc. (Janssen) announced today that ... U.S. Food and Drug Administration (FDA) for the Biologics ... treatment of moderately to severely active rheumatoid arthritis (RA). ... needed to further evaluate the safety of sirukumab in ... "We are disappointed ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer ... one of the most popular and least understood books in the Holy Scriptures, Revelation. ... descriptions that have baffled scholars for centuries. Many have tossed it off as mere ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... for healthcare compliance program management, will showcase a range of technology and learning ... Assisted Living (NCAL) Convention and Expo to be held October 14–18, 2017 at ...
(Date:10/12/2017)... MD (PRWEB) , ... October 12, 2017 , ... The ... of Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual ... – 8. , In honor of Morris F. Collen, a pioneer in the field ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at Children’s National ... 49th Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. ... for Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... the latest in wound care advancements to physician colleagues, skilled nursing facility medical ... titled, "Navigating the Treacherous Waters of Wound Care." , "At many of these ...
Breaking Medicine News(10 mins):